Serotonin-norepinephrine reuptake inhibitors and the influence of binding affinity (Ki) on analgesia

Journal of Clinical Pharmacy and Therapeutics
M RaoufJ Fudin

Abstract

Serotonin-norepinephrine reuptake inhibitors (SNRIs) are commonly used for various psychiatric conditions and neuropathic pain syndromes. SNRIs inhibit the reuptake of serotonin (5-HT) and norepinephrine (NE); however, NE reuptake inhibition is thought to be the primary mediator for their analgesic effect. Key differences in pharmacodynamics and receptor affinities exist between SNRIs. The selectivity for each monoamine differs among SNRIs based on the agent's affinity and activity at the monoamine reuptake transporter. We review differences in receptor affinities and monoamine selectivity among SNRIs and the corresponding clinical impact. The varying selectivity for 5-HT and NE among the SNRIs may help explain the therapeutic dosing required for neuropathic pain as well as dose-related adverse effects. It is important to understand the pharmacologic differences among SNRIs, in addition to the data from clinical trials, to guide their safe and effective use.

References

May 7, 1992·The New England Journal of Medicine·M B MaxR Dubner
Feb 1, 1997·The Annals of Pharmacotherapy·B J Mason, K H Blackburn
Jan 25, 2000·Journal of the Royal Society of Medicine·S Kesavan, G M Sobala
May 12, 2000·Archives of General Psychiatry·A T HarveyS H Preskorn
Jun 10, 2000·Science·C J Woolf, M W Salter
Dec 26, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Mar 13, 2002·European Journal of Pain : EJP·Tiina TasmuthEija Kalso
Feb 17, 1962·Lancet·H E WEBB, R G LASCELLES
Jan 28, 2004·Biological Psychiatry·S Neil VaishnaviMichael J Owens
May 28, 2004·Pharmacotherapy·Dale R GrotheDominick Albano
Jun 1, 2004·The American Journal of Psychiatry·Richard MahlbergJulia Kirchheiner
May 25, 2005·Basic & Clinical Pharmacology & Toxicology·Søren H SindrupTroels S Jensen
May 6, 2006·The Journal of Pharmacology and Experimental Therapeutics·Darlene C DeecherTerrance H Andree
May 13, 2006·The International Journal of Neuropsychopharmacology·Pierre BlierGuy Debonnel
Oct 13, 2006·Progress in Neurobiology·Antti Pertovaara
Jun 16, 2007·Molecular Diagnosis & Therapy·Siew Hua GanWan Zulmi
Jul 25, 2008·Pharmacopsychiatry·M FricJ Deckert
May 16, 2009·Current Pharmaceutical Design·Francisco López-Muñoz, Cecilio Alamo
Dec 4, 2009·Primary Care Companion to the Journal of Clinical Psychiatry·Junji Takeshita, Mark H Litzinger
Jul 24, 2010·Lancet Neurology·Ralf BaronGunnar Wasner
Nov 3, 2010·The Journal of Clinical Investigation·Michael H OssipovFrank Porreca
Mar 24, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J P DurandF Goldwasser
Jun 16, 2012·Expert Opinion on Pharmacotherapy·Robert B RaffaThomas M Tzschentke
Aug 21, 2013·Arthritis Research & Therapy·Daniel J ClauwYong Wang
Oct 3, 2013·Journal of Analytical Toxicology·Isabel CostaRicardo Jorge Dinis-Oliveira
Jan 5, 2014·The Cochrane Database of Systematic Reviews·Michael P T LunnPhilip J Wiffen
Feb 15, 2014·Expert Review of Clinical Pharmacology·Rajnish MagoMichael E Thase
Aug 8, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Collin ZimmermanCharles L Loprinzi
Jan 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J P DurandF Goldwasser

❮ Previous
Next ❯

Citations

May 19, 2020·The Mental Health Clinician·Andrea D MekonnenTheresa K Hoffman
Jan 30, 2021·The Senior Care Pharmacist·Demetra AntimisiarisCortney Mospan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.